Analyst Eva Fortea Verdejo of Wells Fargo maintained a Buy rating on iTeos Therapeutics (ITOS – Research Report), retaining the price target of $31.00. Eva Fortea Verdejo’s rating is based on several ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for Lycia, Attovia ...

On Friday, iTeos Therapeutics Inc (ITOS) stock saw a modest uptick, ending the day at $8.81 which represents a slight increase of $0.36 or 4.26% from the prior close of $8.45. The stock opened at ...

iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 4,820,000 shares ...

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with ...

Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.